1
|
Lafage-Proust MH, Lapierre V, Jannot M, Normand M, Sornay-Rendu E, Szulc P, Thomas T, Mariat C, Chapurlat R. FP586BONE STATUS OF CKD5 PATIENTS WAIT-LISTED FOR KIDNEY TRANSPLANTATION IS POORLY EVALUATED BY DXA. Nephrol Dial Transplant 2018. [DOI: 10.1093/ndt/gfy104.fp586] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
| | - Vanessa Lapierre
- Rhumatology, University Hospital-INSERM U1059, Saint-Etienne, France
| | - Martin Jannot
- Nephrology, University Hospital, Saint-Etienne, France
| | - Myriam Normand
- Rhumatology, University Hospital-INSERM U1059, Saint-Etienne, France
| | | | - Pawel Szulc
- Rhumatology, University Hospital-INSERM U1033, Lyon, France
| | - Thierry Thomas
- Rhumatology, University Hospital-INSERM U1059, Saint-Etienne, France
| | | | | |
Collapse
|
2
|
Adler M, Lapierre V, Bourhis J, Castilla-Llorente C, Gachot B, Wyplosz B. Persistance des anticorps anti-amariles post-vaccinaux chez les receveurs de greffe allogénique. Med Mal Infect 2017. [DOI: 10.1016/j.medmal.2017.03.319] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
3
|
Lapierre V, Alexandrova K. Immunoadsorption procedures is feasible even with very low platelets count in order to restore a post-platelet transfusion increment. Cytotherapy 2017. [DOI: 10.1016/j.jcyt.2017.02.186] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
4
|
Richard S, Lapierre V, Girerd N, Bonnerot M, Burkhard PR, Lagerstedt L, Bracard S, Debouverie M, Turck N, Sanchez JC. Diagnostic performance of peroxiredoxin 1 to determine time-of-onset of acute cerebral infarction. Sci Rep 2016; 6:38300. [PMID: 27924073 PMCID: PMC5141372 DOI: 10.1038/srep38300] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/13/2016] [Accepted: 11/07/2016] [Indexed: 01/07/2023] Open
Abstract
Accurately determining time-of-onset of cerebral infarction is important to clearly identify patients who could benefit from reperfusion therapies. We assessed the kinetics of peroxiredoxin 1 (PRDX1), a protein involved in oxidative stress during the acute phase of ischemia, and its ability to determine stroke onset in a population of patients with known onset of less than 24 hours and in a control group. Median PRDX1 levels were significantly higher in stroke patients compared to controls. PRDX1 levels were also higher from blood samples withdrawn before vs. after 3 hours following stroke onset, and before vs. after 6 hours. ROC analysis with area under the curve (AUC), sensitivity (Se) and specificity (Sp) determined from the Youden index was performed to assess the ability of PRDX1 levels to determine onset. Diagnostic performances of PRDX1 levels were defined by an AUC of 69%, Se of 53% and Sp of 86% for identifying cerebral infarction occurring <3 hours, and an AUC of 68%, Se of 49% and Sp of 88% for cerebral infarction occurring <6 hours. These first results suggest that PRDX1 levels could be the basis of a new method using biomarkers for determining cerebral infarction onset.
Collapse
Affiliation(s)
- Sébastien Richard
- Department of Neurology, Stroke Unit, University Hospital of Nancy, 54035 Nancy, France.,Centre d'Investigation Clinique Plurithématique CIC 1433, University Hospital of Nancy, 54500 Vandoeuvre-lès-Nancy, France.,Department of Human Protein Sciences, University Medical Center, 1206 Geneva, Switzerland
| | - Vanessa Lapierre
- Department of Human Protein Sciences, University Medical Center, 1206 Geneva, Switzerland
| | - Nicolas Girerd
- Centre d'Investigation Clinique Plurithématique CIC 1433, University Hospital of Nancy, 54500 Vandoeuvre-lès-Nancy, France
| | - Mathieu Bonnerot
- Department of Neurology, Stroke Unit, University Hospital of Nancy, 54035 Nancy, France
| | - Pierre R Burkhard
- Department of Neurology, University Hospital of Geneva, 1205 Geneva, Switzerland
| | - Linnéa Lagerstedt
- Department of Human Protein Sciences, University Medical Center, 1206 Geneva, Switzerland
| | - Serge Bracard
- Department of Neuroradiology, University Hospital of Nancy, 54035 Nancy, France
| | - Marc Debouverie
- Department of Neurology, Stroke Unit, University Hospital of Nancy, 54035 Nancy, France
| | - Natacha Turck
- Department of Human Protein Sciences, University Medical Center, 1206 Geneva, Switzerland
| | - Jean-Charles Sanchez
- Department of Human Protein Sciences, University Medical Center, 1206 Geneva, Switzerland
| |
Collapse
|
5
|
Palazzo A, Bluteau O, Messaoudi K, Marangoni F, Chang Y, Souquere S, Pierron G, Lapierre V, Zheng Y, Vainchenker W, Raslova H, Debili N. The cell division control protein 42-Src family kinase-neural Wiskott-Aldrich syndrome protein pathway regulates human proplatelet formation. J Thromb Haemost 2016; 14:2524-2535. [PMID: 27685868 DOI: 10.1111/jth.13519] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2016] [Indexed: 12/31/2022]
Abstract
Essentials The role of the cytoskeleton during megakaryocyte differentiation was examined. Human megakaryocytes are derived from in vitro cultured CD34+ cells. Cell division control protein 42 (CDC42) positively regulates proplatelet formation (PPF). Neural Wiskott-Aldrich syndrome protein, the main effector of CDC42 with Src positively regulates PPF. SUMMARY Background Cytoskeletal rearrangements are essential for platelet release. The RHO small GTPase family, as regulators of the actin cytoskeleton, play an important role in proplatelet formation (PPF). In the neuronal system, CDC42 is involved in axon formation, a process that combines elongation and branching as for PPF. Objective To analyze the role of CDC42 and its effectors of the Wiskott-Aldrich syndrome protein (WASP) family in PPF. Methods Human megakaryocytes (MKs) were obtained from CD34+ cells. Inhibition of CDC42 in MKs was performed with the chemical inhibitor CASIN or with an active or a dominant-negative form of CDC42. The knock-down of N-WASP was obtained with a small hairpin RNA strategy Results Herein, we show that CDC42 activity increased during MK differentiation. The use of the chemical inhibitor CASIN or of an active or a dominant-negative form of CDC42 demonstrated that CDC42 positively regulated PPF in vitro. We determined that N-WASP, but not WASP, regulated PPF. We found that N-WASP knockdown led to a marked decrease in PPF, owing to a defect in the demarcation membrane system (DMS). This was associated with RHOA activation, and a concomitant augmentation in the phosphorylation of mysosin light chain 2. Phosphorylation of N-WASP, creating a primed form of N-WASP, increased during MK differentiation. Phosphorylation inhibition by two Src family kinase inhibitors decreased PPF. Conclusions We conclude that N-WASP positively regulates DMS development and PPF, and that the Src family kinases in association with CDC42 regulate PPF through N-WASP.
Collapse
Affiliation(s)
- A Palazzo
- Institut National de la Santé et de la Recherche Médicale, UMR 1170, Equipe labellisée Ligue Contre le Cancer, Laboratoire d'Excellence GR-Ex, Villejuif, France
- Université Paris-Saclay, UMR 1170, Villejuif, France
- Gustave Roussy, UMR 1170, Villejuif, France
| | - O Bluteau
- Institut National de la Santé et de la Recherche Médicale, UMR 1170, Equipe labellisée Ligue Contre le Cancer, Laboratoire d'Excellence GR-Ex, Villejuif, France
- Université Paris-Saclay, UMR 1170, Villejuif, France
- Gustave Roussy, UMR 1170, Villejuif, France
| | - K Messaoudi
- Institut National de la Santé et de la Recherche Médicale, UMR 1170, Equipe labellisée Ligue Contre le Cancer, Laboratoire d'Excellence GR-Ex, Villejuif, France
- Université Paris-Saclay, UMR 1170, Villejuif, France
- Gustave Roussy, UMR 1170, Villejuif, France
| | - F Marangoni
- Institut National de la Santé et de la Recherche Médicale, UMR 1170, Equipe labellisée Ligue Contre le Cancer, Laboratoire d'Excellence GR-Ex, Villejuif, France
- Université Paris-Saclay, UMR 1170, Villejuif, France
- Gustave Roussy, UMR 1170, Villejuif, France
| | - Y Chang
- Institut National de la Santé et de la Recherche Médicale, UMR 1170, Equipe labellisée Ligue Contre le Cancer, Laboratoire d'Excellence GR-Ex, Villejuif, France
- Université Paris-Saclay, UMR 1170, Villejuif, France
- Gustave Roussy, UMR 1170, Villejuif, France
| | - S Souquere
- Gustave Roussy, Centre Nationale de la Recherche Scientifique, UMR 8122, Gustave Roussy, Villejuif, France
| | - G Pierron
- Gustave Roussy, Centre Nationale de la Recherche Scientifique, UMR 8122, Gustave Roussy, Villejuif, France
| | - V Lapierre
- Gustave Roussy, Unité de Thérapie Cellulaire, Villejuif, France
| | - Y Zheng
- Division of Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH, USA
| | - W Vainchenker
- Institut National de la Santé et de la Recherche Médicale, UMR 1170, Equipe labellisée Ligue Contre le Cancer, Laboratoire d'Excellence GR-Ex, Villejuif, France
- Université Paris-Saclay, UMR 1170, Villejuif, France
- Gustave Roussy, UMR 1170, Villejuif, France
| | - H Raslova
- Institut National de la Santé et de la Recherche Médicale, UMR 1170, Equipe labellisée Ligue Contre le Cancer, Laboratoire d'Excellence GR-Ex, Villejuif, France
- Université Paris-Saclay, UMR 1170, Villejuif, France
- Gustave Roussy, UMR 1170, Villejuif, France
| | - N Debili
- Institut National de la Santé et de la Recherche Médicale, UMR 1170, Equipe labellisée Ligue Contre le Cancer, Laboratoire d'Excellence GR-Ex, Villejuif, France
- Université Paris-Saclay, UMR 1170, Villejuif, France
- Gustave Roussy, UMR 1170, Villejuif, France
| |
Collapse
|
6
|
Chiche-Lapierre C, Tramalloni D, Chaput N, Lapierre V. Comparative Analysis of Sepax S-100, COBE 2991, and Manual DMSO Removal Techniques From Cryopreserved Hematopoietic Stem Cell Apheresis Product. Cytotherapy 2016. [DOI: 10.1016/j.jcyt.2016.03.112] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
7
|
Pasqualini C, Dufour C, Goma G, Raquin MA, Lapierre V, Valteau-Couanet D. Tandem high-dose chemotherapy with thiotepa and busulfan–melphalan and autologous stem cell transplantation in very high-risk neuroblastoma patients. Bone Marrow Transplant 2015; 51:227-31. [DOI: 10.1038/bmt.2015.264] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2015] [Revised: 09/24/2015] [Accepted: 09/29/2015] [Indexed: 11/09/2022]
|
8
|
|
9
|
|
10
|
Lapierre V, Rossi JF, Heshmati F, Azar N, Vekhof A, Makowski C, Moreau P, Caillot D, Auperin A, Chabannon C. Ancestim (r-metHuSCF) plus filgrastim and/or chemotherapy for mobilization of blood progenitors in 513 poorly mobilizing cancer patients: the French compassionate experience. Bone Marrow Transplant 2010; 46:936-42. [PMID: 20956952 DOI: 10.1038/bmt.2010.231] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
Ancestim (r-MetHuSCF) is available in France for compassionate use in patients who are candidates for high-dose chemotherapy and autologous transplantation, and who failed in previous attempts at mobilization and collection. We report here data from 513 adult patients who benefited from this program, between January 1998 and July 2007. Given with systematic premedication, ancestim was generally well tolerated, although severe but not life-threatening adverse events were reported in 12 individuals. Overall, a graft was obtained or completed for 235 patients (46%). The median number of collected CD34+ cells was 3.00 × 10(6)/kg (range: 0.03-39.50). The target threshold of 2 × 10(6) CD34+ cells/kg was reached in 161 patients (31%). Factors associated with collection were diagnosis of myeloma, no previous autologous transplant, no more than one previous failed attempt and a mobilization regimen including cytotoxic agents. A total of 207 patients (40%) proceeded to high-dose chemotherapy and autologous transplantation. The median time to reach 0.5 × 10(9)/L neutrophils and 20 × 10(9)/L platelets was 12 (6-40) and 13 (0-31) days, respectively. We conclude that a combination of ancestim with filgrastim successfully mobilized CD34+ cells in peripheral blood, and allowed adequate collection in preparation for autologous transplantation in approximately one-third of poorly mobilizing patients.
Collapse
Affiliation(s)
- V Lapierre
- Institut Gustave Roussy, Villejuif, France.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Panterne B, Richard MJ, Sabatini C, Pouthier F, Mouillot L, Bardey D, Boulanger F, Créa S, Dal Cortivo L, Decot V, Fleury-Cappellesso S, Giraud C, Lapierre V, Léauté AG, Le Berre C, Lemarié C, Piard N, Rapatel C, Rosenzwajg M. [Quality control of defrosted cord blood units: results from an inter-laboratory study]. Transfus Clin Biol 2010; 17:41-6. [PMID: 20674441 DOI: 10.1016/j.tracli.2010.06.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2010] [Accepted: 06/07/2010] [Indexed: 10/19/2022]
Abstract
PURPOSE Today, haematopoietic stem cell graft from placental blood concerns more than 15 % of allogeneic grafts. An inter-laboratory study of the quality control of defrosted cord blood units has been coordinated by the French society for cell and tissue bioengineering (SFBCT), with the cord blood bank of Bourgogne Franche-Comté and controlled by the French health products safety agency (Afssaps). The aim of this study is to ensure the inter-laboratory reproducibility of the quality controls practised by the banks during defrosting. The cellular outputs were analyzed according to the defrosting techniques, according to the method used in flow cytometry: single-platform (SP) versus double-platform (DP), or the product nature, i.e. in total blood or miniaturized. METHODS Forty-two units of placental blood (USP), which were out of range were provided for defrosting to 14 participating sites. USP were defrosted and controlled according to the procedures of each bank. Once the USP is defrosted, a part of the product was controlled by the site and the other part by Afssaps. Following controls were carried out: numeration of the total nucleated cells (TNC) and of CD34+ cells (made by a SP method in Afssaps) and functional assay. RESULTS Concerning TNC, the defrosting sites obtained a cellular output of 94 %+/-28 in day 0 compared with an output of 72 %+/-24 in Afssaps showing a rather good stability of the USP transmitted with an average deviation of 23 %+/-22. The freezing process with or without reduction of volume does not affect this variation. Concerning the numeration of CD34+ cells, the average deviation between the participating sites and Afssaps was 29 %+/-23 compared with 21 %+/-16 for the sites using a SP method against 47 %+/-25 for those using a DP method. The CD34+ outputs are equal to 82 % +/- 60 in day 0 for the participating sites against 52 %+/-20 for Afssaps. For the sites using a DP method, it is stressed that this output is particularly high with a rate of 126 %+/-90 (n=15) whereas it is 62 %+/-20 (n=32) for the sites using a SP method. CONCLUSION These results underline a good stability of viable CD34+ cells and a greater reliability of the SP methods for the CD34+ cell numeration for these defrosted USP. Lastly, the results of the functional assay regarding the average clonogenicities (equal to 15 %) reinforce the conclusions on the quality of the defrosted products.
Collapse
Affiliation(s)
- B Panterne
- Afssaps, DLC, unité produits sanguins et thérapie cellulaire, 143/147, boulevard Anatole-France, 93285 St-Denis cedex, France.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
12
|
Lemarie C, Esterni B, Calmels B, Dazey B, Lapierre V, Lecchi L, Meyer A, Rea D, Thuret I, Chambost H, Curtillet C, Chabannon C, Michel G. CD34+ progenitors are reproducibly recovered in thawed umbilical grafts, and positively influence haematopoietic reconstitution after transplantation. Bone Marrow Transplant 2007; 39:453-60. [PMID: 17334384 DOI: 10.1038/sj.bmt.1705618] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Cord blood (CB) units are increasingly used for allogeneic transplantation. Cell dose, a major factor for CB selection, is evaluated before freezing by each CB bank, using various techniques. This may introduce variability and affect the prediction of cell recovery after thawing, or haematopoietic reconstitution. Forty-two children were transplanted at the same institution with unrelated CB units. All units were thawed and evaluated at the same cell therapy facility, using standard procedures. We investigated: (i) factors that affect cell loss after thawing, and (ii) the importance of CD34(+) cell doses. Prefreeze and post-thaw CD34(+) cell doses were statistically correlated, thus suggesting that variability in numeration techniques used by different CB banks does not compromise the biological and clinical value of these figures. CD34(+) cell recovery appeared to be correlated with the absolute number of CD34(+) cells per frozen bag. Infused CD34(+) is the cell dose that better correlates with platelet reconstitution delay; in addition, when using a quartile comparison, haematopoietic recovery appeared to be related with prefreeze and post-thaw CD34(+) cell doses. We conclude that enumeration of CD34(+) cells in CB units is of biological significance, and may help select CB units and identify patients at risk of delayed recovery.
Collapse
Affiliation(s)
- C Lemarie
- Centre de Thérapie Cellulaire et Génique, Département de Biologie, Institut Paoli-Calmettes, Marseille, France.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Lapierre V, Pellegrini N, Bardey I, Malugani C, Saas P, Garnache F, Racadot E, Schillinger F, Maddens S. Cord blood volume reduction using an automated system (Sepax) vs. a semi-automated system (Optipress II) and a manual method (hydroxyethyl starch sedimentation) for routine cord blood banking: a comparative study. Cytotherapy 2007; 9:165-9. [PMID: 17453968 DOI: 10.1080/14653240701196811] [Citation(s) in RCA: 37] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Abstract
Background With the development of cord blood banking, solutions have to be found to solve the storage space problem, by reducing the volume of cord blood units (CBU). Methods We compared total nucleated cell (TNC) and CD34(+) cell counts before and after processing with three different CBU volume reduction methods used consecutively in our bank: a manual method based on hydroxyethyl starch sedimentation (HES) (n=447), a top-and-bottom (TB) semi-automated method (n=181) using Optipress II, and the Sepax automated method (n=213). Statistical analysis was done using t-tests, linear regression and Spearman correlation coefficients. Adjusted variables included TNC, CD34(+) cell counts, CD34(+) cell percentage and CB volume before processing. Results TNC recovery was higher with Sepax (80.3+/-7.7%) than with HES (76.8+/-9.1%) and TB (60.7+/-13.5%) (P<0.0001, both). It was higher with HES than with TB (P<0.0001). CD34(+) cell recovery was higher with Sepax (86+/-11.6%) than with HES (81.5+/-12.5%) and TB (82.0+/-17.7%) (P<0.008 and <0.0001, respectively) and results with HES and TB were not significantly different (P=0.7). Interestingly, with Sepax, TNC and CD34(+) cell recoveries were not correlated with pre-processing values (P=0.8 and 0.4, respectively). Discussion In conclusion, the Sepax volume reduction method allows higher TNC and CD34(+) cell recoveries.
Collapse
Affiliation(s)
- V Lapierre
- Besançon Cord Blood Bank, Besançon, France.
| | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Tramalloni D, Aupérin A, Oubouzar N, Lapierre V. Implication du personnel infirmier dans la sécurité transfusionnelle : évaluation des connaissances et de la pratique à l'institut Gustave-Roussy. Transfus Clin Biol 2005; 12:427-32. [PMID: 16616570 DOI: 10.1016/j.tracli.2006.02.024] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2005] [Accepted: 02/27/2006] [Indexed: 11/20/2022]
Abstract
BACKGROUND A first survey on nurses transfusion practices at our Hospital revealed poor knowledge. Good Transfusion Practices were written, a training program was implemented and a second survey was carried out two years later. STUDY DESIGN AN METHODS: We conducted the second survey in which 4 of the questions were identical to those in the first survey in order to assess the impact of this training strategy. The 4 questions were on blood sample identification, checking patient identification, checking "use by date" on blood product bag and the pre-transfusion bedside compatibility test. Behaviours were evaluated by checking the pre-transfusion procedures, including interpretation of bedside compatibility tests. We investigated the impact of attendance at the training course, the period of employment, day versus night shift and attempted to correlate these factors with the results of the second survey. RESULTS A significant improvement was observed in knowledge of Good Practices between the first and the second survey (P = 10(-4)). However, the multivariate analysis showed that the impact of training was heterogeneous. Pre-transfusion protocol checks have improved significantly (P = 0.05) as well as pre-transfusion bedside compatibility test interpretation of ABO compatibility (P = 0.007). CONCLUSION In our study, the implementation of Good practices has significantly improved nurses' knowledge about transfusion safety requirements but it is essential to continue and adapt the training and cheek regularly the impact of these implementations.
Collapse
Affiliation(s)
- D Tramalloni
- Unité de médecine transfusionnelle et d'hémovigilance, institut Gustave-Roussy, Villejuif, France
| | | | | | | |
Collapse
|
15
|
Creuzot-Garcher C, Lafontaine PO, Brignole F, Pisella PJ, d'Athis P, Bron A, Lapierre V, Baudouin C. Traitement des syndromes secs graves par sérum autologue. J Fr Ophtalmol 2004; 27:346-51. [PMID: 15173640 DOI: 10.1016/s0181-5512(04)96139-6] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
BACKGROUND Dry eye syndrome with tear deficiency can be improved with artificial tears, which can be associated with topical anti-inflammatory agents. Autologous serum can provide the ocular surface with beneficial growth factors and vitamins. PATIENTS AND METHODS Twenty-one patients suffering from severe dry eye due to Sjögren's syndrome were treated with 20% autologous serum for 2 Months. The Schirmer I test, break-up time, and fluorescein and lissamine green stainings were performed before and after treatment. Subjective complaints such as burning, foreign body sensation, dryness and photophobia were assessed by a questionnaire as well as a face score reflecting the current condition of patients' eyes. RESULTS Lissamine green and fluorescein scores improved significantly as well as subjective symptoms of burning, foreign body sensation and dryness (p<0.05). The face score was significantly improved. Bacterial culture of serum delivered to the patients all remained negative. DISCUSSION Autologous serum provides growth factors and vitamins that are useful for an altered ocular surface due to Sjögren's disease. However, some problems still remain: risk of contamination, arbitrary dilution of autologous serum, and a current lack of regulations for use of autologous serum. A close collaboration between ophthalmologists and the Etablissement Français du Sang (French Blood Bank) is mandatory because autologous serum should be considered as a useful tool to treat severe ocular surface disorders. CONCLUSION The use of autologous serum improved symptoms and objective signs caused by severe Sjögren's syndrome. Currently, a lack of clear regulations prevents its widespread use in severe ocular surface disorders.
Collapse
Affiliation(s)
- C Creuzot-Garcher
- Service d'Ophtalmologie, CHU, 3, rue du Faubourg Raines, 21000 Dijon.
| | | | | | | | | | | | | | | |
Collapse
|
16
|
Thirion X, Lapierre V, Micallef J, Ronflé E, Masut A, Pradel V, Coudert C, Mabriez JC, Sanmarco JL. Buprenorphine prescription by general practitioners in a French region. Drug Alcohol Depend 2002; 65:197-204. [PMID: 11772481 DOI: 10.1016/s0376-8716(01)00161-2] [Citation(s) in RCA: 74] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Since 1996 French general practitioners (GPs) may prescribe sublingual buprenorphine tablets as maintenance treatment for opiate dependence. The computerised data management of the main French health reimbursement system now allows surveillance of the use of this drug, and how it is prescribed. The purpose of this study is to determine the profile of maintained patients, prescribed doses, associated psychotropic treatments and how practitioners prescribe these treatments. This study analyses the 11186 buprenorphine prescriptions electronically transmitted for reimbursement between September and December 1999 in a specific French region. It was found that the 2078 treated patients consumed a mean of 11.5 mg of buprenorphine per day and 12% of them procured prescriptions from more than two prescribers. 43% of maintained patients had an associated benzodiazepine prescription, mainly flunitrazepam, often on the same prescription form. 61% of patients had regular follow-up, others had occasional consultations (21%) and another 18% had deviant maintenance treatment (more than two prescribers or more than 20 mg per day of daily buprenorphine dose). Benzodiazepine consumption was much higher in the 'deviant group' (71.4%). 85% of buprenorphine prescriptions were made by GPs. 21% of GPs prescribed buprenorphine and 61% of those had only one or two maintained patients. Buprenorphine prescription by French GPs is a procedure with no particular requirements, allowing many patients to easily access maintenance treatments. However, a high risk of abuse exists, which demands extensive investigation and evaluation of these practices.
Collapse
Affiliation(s)
- X Thirion
- Centre for Evaluation and Information on Pharmacodependence, Public Health Department, School of Medicine, 27 Boulevard Jean Moulin, 13005 Marseilles, France.
| | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Tayebi H, Lapierre V, Saas P, Lienard A, Sutton L, Milpied N, Attal M, Cahn JY, Kuentz M, Blaise D, Hervé P, Tiberghien P, Robinet E. Enhanced activation of B cells in a granulocyte colony-stimulating factor-mobilized peripheral blood stem cell graft. Br J Haematol 2001; 114:698-700. [PMID: 11553000 DOI: 10.1046/j.1365-2141.2001.02965.x] [Citation(s) in RCA: 21] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
In a randomized study that compared human leucocyte antigen-identical allogeneic granulocyte colony-stimulating factor (G-CSF)-mobilized peripheral blood stem cell (PBSC) versus bone marrow (BM) transplantation, the expression of activation markers, CD23, CD25 and CD45RO by B cells, was compared in blood before and after G-CSF mobilization and in PBSC versus BM grafts. The fractions of CD23+ and CD25+ B cells were higher in PBSC than in BM grafts. Moreover, we observed a G-CSF-induced increase in B-cell fractions in blood as well as in PBSC grafts when compared with BM grafts. Such an enhanced B-cell activation could contribute to the accelerated kinetics of immuno-haematological reconstitution, the occurrence of acute haemolysis in the ABO minor incompatibility setting, as well as the increased incidence of chronic graft-versus-host disease observed after PBSC transplantation.
Collapse
Affiliation(s)
- H Tayebi
- Laboratoire de Thérapeutique Immuno-Moléculaire, INSERM, E-0119, UPRES EA-2284, Etablissement Français du Sang-Bourgogne/Franche Comté, Besançon, France
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
18
|
Lapierre V, Oubouzar N, Aupérin A, Tramalloni D, Tayebi H, Robinet E, Kuentz M, Blaise D, Hartmann O, Hervé P, Tiberghien P. Influence of the hematopoietic stem cell source on early immunohematologic reconstitution after allogeneic transplantation. Blood 2001; 97:2580-6. [PMID: 11313245 DOI: 10.1182/blood.v97.9.2580] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Several acute hemolysis episodes, sometimes lethal, have been recently described after transplantation of allogeneic peripheral blood hematopoietic stem cells (PBHSCs). Hemolysis resulted from the production of donor-derived antibodies (Abs) directed at ABO antigens (Ags) present on recipient red blood cells (RBCs). A multicenter randomized phase III clinical study comparing allogeneic PBHSC transplantation (PBHSCT) versus bone marrow hematopoietic stem cell transplantation (BMHSCT) has been conducted in France. In the course of this study, serum anti-A and/or anti-B Ab titers were compared before the conditioning regimen and on day +30 after transplantation in 49 consecutive evaluable PBHSCT (n = 21) or BMHSCT (n = 28) recipients. PBHSCT resulted in a higher frequency of increased anti-A and/or anti-B Ab titers 30 days after transplantation as compared to BMHSCT: 8 (38%) of 21 versus 3 (11%) of 28 (P =.04). In PBHSCT recipients, increased titers were observed mostly after receiving a minor ABO mismatch transplant: 5 of 7 versus 3 of 14 in the absence of any minor ABO mismatch (P =.05), whereas this was not the case after BMHSCT: 1 of 8 versus 2 of 20. Anti-A and/or anti-B serum Abs detectable at day +30 after PBHSCT were always directed against A and/or B Ags absent both on donor and recipient RBCs. Finally, 3 of 21 PBHSCT versus 0 of 28 BMHSCT recipients developed anti-allogeneic RBC Abs other than ABO (P =.07). Overall, the data strongly suggest that immunohematologic reconstitution differs significantly after granulocyte colony-stimulating factor-mobilized PBHSCT when compared to BMHSCT. Such a difference could contribute to the acute hemolysis described after PBHSCT as well as to distinct alloreactivity after PBHSCT.
Collapse
Affiliation(s)
- V Lapierre
- Unité de Médecine Transfusionnelle et d'Hémovigilance, the Comité de Sécurité Transfusionnelle et d'Hémovigilance, and the Service d'Epidémiologie et de Biostatistique, Institut Gustave Roussy, Villejuif, France.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Tayebi H, Kuttler F, Saas P, Lienard A, Petracca B, Lapierre V, Ferrand C, Fest T, Cahn J, Blaise D, Kuentz M, Hervé P, Tiberghien P, Robinet E. Effect of granulocyte colony-stimulating factor mobilization on phenotypical and functional properties of immune cells. Exp Hematol 2001; 29:458-70. [PMID: 11301186 DOI: 10.1016/s0301-472x(01)00613-0] [Citation(s) in RCA: 71] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
Some phenotypic and functional properties of lymphocytes from bone marrow or peripheral blood stem cell donors were compared in a randomized study. Lymphocyte subsets were analyzed by immunocytometry in blood harvested from bone marrow donors (n = 27) and from peripheral blood stem cell donors before and after granulocyte colony-stimulating factor mobilization (n = 23) and in bone marrow and peripheral blood stem cell grafts. Granulocyte colony-stimulating factor mobilization increased the blood T and B, but not NK, lymphocyte counts. All lymphocyte counts were approximately 10-fold higher in peripheral blood stem cell grafts than in bone marrow grafts. Analysis of CD25, CD95, HLA-DR, and CD45RA expression shows that T-cell activation level was lower after granulocyte colony-stimulating factor mobilization. Similarly, granulocyte colony-stimulating factor reduced by twofold to threefold the percentage of interferon-gamma, interleukin-2, and tumor necrosis factor-alpha-secreting cells within the NK, NK-T, and T-cell subsets and severely impaired the potential for interferon-gamma production at the single-cell level. mRNA levels of both type 1 (interferon-gamma, interleukin-2) and type 2 (interleukin-4, interleukin-13) cytokines were approximately 10-fold lower in peripheral blood stem cell grafts than in bone marrow grafts. This reduced potential of cytokine production was not associated with a preferential mobilization of so-called "suppressive" cells (CD3+CD4-CD8-, CD3+CD8+CD56+, or CD3+TCRVA24+CD161+), nor with a modulation of killer cell receptors CD161, NKB1, and CD94 expression by NK, NK-T, or T cells. Our data demonstrate in a randomized setting that quantitative as well as qualitative differences exist between a bone marrow and a peripheral blood stem cell graft, whose ability to produce type 1 and type 2 cytokines is impaired.
Collapse
Affiliation(s)
- H Tayebi
- Etablissement Français du Sang Bourgogne/Franche-Comté, 1, Bd Alexandre Fleming, 25020 Besançon cedex, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
20
|
Tayebi H, Tiberghien P, Ferrand C, Lienard A, Duperrier A, Cahn JY, Lapierre V, Saas P, Kuentz M, Blaise D, Hervé P, Robinet E. Allogeneic peripheral blood stem cell transplantation results in less alteration of early T cell compartment homeostasis than bone marrow transplantation. Bone Marrow Transplant 2001; 27:167-75. [PMID: 11281386 DOI: 10.1038/sj.bmt.1702753] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Since low T cell counts evaluated 1 month after allogeneic bone marrow transplantation (BMT) are associated with an increased risk of leukemia relapse (Powles et al., Blood 1998; 91: 3481-3486), we compared, in a randomized multicentric clinical study, the peripheral blood cells obtained 30 days after allogeneic BMT vs allogeneic G-CSF-mobilized peripheral blood stem cell transplantation (BCT) in an HLA-identical setting. T cell counts were higher 30 days after BCT (718+/-142 cells/microl, n = 20) than after BMT (271+/-53 cells/microl, n = 26, P = 0.006). However, T cells were less activated after BCT than after BMT, as demonstrated by a lower expression level of CD25 and a lower percentage of HLA-DR+ and CD95+ T cells. Furthermore, CD4+, CD8+ and CD45RA+ post-BCT T cell counts correlated with the number of cells infused with the PBSC graft, while such a correlation was not observed between post-BMT counts and BM graft cell numbers, suggesting that the intensity of post-transplant peripheral lymphoid expansion and/or deletion differed between BCT and BMT. A comparison of the input of T cells expressing different CD45 isoforms with the post-transplant cell recovery further confirmed that, within the CD4+ T cell subset, post-transplant expansions occurred at a higher level after BMT than after BCT, affecting mainly the CD4+ CD45RO+ subset. Altogether, our data demonstrate for the first time in a randomized setting that homeostasis of the T cell pool is less altered early after BCT than after BMT. This may have a strong impact on the graft-versus-leukemia (GVL) effect and subsequent relapse rate.
Collapse
Affiliation(s)
- H Tayebi
- Etablissement Français du Sang-Bourgogne/Franche-Comté, Besaçon, France
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
21
|
Abstract
OBJECTIVES Intraoperative blood cells salvage using a Cell Saver technique is controversial in oncologic surgery because tumor cells could be aspirated and reinfused to the patient. The goal of this review was to discuss the risk associated with this technique, and the way to minimize it. DATA SOURCES A review of the literature has been made by questioning PubMed site (http://nbci.nlm.nih.gov) on the period of 1968 to 2000. The key words were: intraoperative blood salvage, blood transfusion, autologous, cancer. Cases reports have been excluded. STUDY SELECTION Tumor cells aspirated and reinfused have been numbered in both experimental and clinical studies. In clinical studies, the outcome after intraoperative cells salvage/reinfusion has been compared to published data or historical groups of allogeneic transfusion, all in non randomized studies. DATA SYNTHESIS Both experimental and clinical studies confirmed the presence of cancer cells in the blood either aspirated or reinfused. However, six clinical studies with limited number of patients did not show metastatic spread associated with Cell Saver. The addition of leukocyte filters reduces greatly this quantity of cancer cells. Irradiation of the pack did not destroy tumor cells but blocked their proliferative capacity. In the other hand, some infiltrative tumors were shown to have permanent cancer cells seeding, quantitatively superior to the seeding observed when a Cell Saver is used. CONCLUSION It seems reasonable to use the Cell Saver in oncologic surgery, if possible with a leukocyte filter, not only in case of unexpected major bleeding (consensus), but also in programmed cases with high risk of huge hemorrhage.
Collapse
Affiliation(s)
- D Elias
- Service de chirurgie carcinologique générale, institut Gustave-Roussy, 39, rue Camille-Desmoulins, 94805 Villejuif, France.
| | | | | |
Collapse
|
22
|
Valteau-Couanet D, Benhamou E, Vassal G, Stambouli F, Lapierre V, Couanet D, Lumbroso J, Hartmann O. Consolidation with a busulfan-containing regimen followed by stem cell transplantation in infants with poor prognosis stage 4 neuroblastoma. Bone Marrow Transplant 2000; 25:937-42. [PMID: 10800060 DOI: 10.1038/sj.bmt.1702376] [Citation(s) in RCA: 35] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Abstract
Although infants with stage 4 neuroblastoma (NB) usually have a good prognosis, metastatic relapses after 1 year of age and amplification of the N-myc oncogene are established poor prognostic factors. In order to improve the survival of patients with such high-risk factors, we performed consolidation with a busulfan (600 mg/m2)-melphalan (140 mg/m2)-containing regimen followed by autologous stem cell transplantation (SCT). From 1986 to 1998, 12 patients were treated according to this strategy. Their median age at diagnosis was 9 months (1-11). Consolidation was performed after a metastatic relapse in five children, because of persistent bone metastases in one and as first-line consolidation in six patients whose tumor exhibited N-myc amplification. The 5-year EFS rate is 64. 5% (36-85%) with a median follow-up of 92 months (20-126). One toxicity-related death occurred in a very heavily pretreated patient. Hepatic veno-occlusive disease was the major side-effect that occurred in nine of 12 children. This busulfan-melphalan combination appears to dramatically improve the prognosis of these high-risk infants with metastatic NB. Given its high toxicity, indications for this consolidation must be restricted to high-risk infants and a lower dose of busulfan (480 mg/m2) is recommended in children weighing less than 10 kg. Bone Marrow Transplantation (2000) 25, 937-942.
Collapse
|
23
|
Abstract
The transfusion unit of the Institut Gustave Roussy has tested seven pre-transfusion ABO control devices registered at the Agence française de sécurité sanitaire et des produits de santé. Determination of the optimal plan to replace the existing plan in our institution was the primary objective of this study. A significant heterogeneity was observed among tested devices. None of the tested plans fulfilled all the desired quality criteria.
Collapse
Affiliation(s)
- D Tramalloni
- Comité de sécurité transfusionnelle et d'hémovigilance, Institut Gustave-Roussy, Villejuif, France
| | | | | | | | | |
Collapse
|
24
|
Lapierre V, Kuentz M, Tiberghien P. Allogeneic peripheral blood hematopoietic stem cell transplantation: guidelines for red blood cell immuno-hematological assessment and transfusion practice.Société Française de Greffe de Moelle. Bone Marrow Transplant 2000; 25:507-12. [PMID: 10713627 DOI: 10.1038/sj.bmt.1702203] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Allogeneic peripheral blood hematopoietic stem cell transplantation (PBSCT) is presently being evaluated in a French randomized study comparing peripheral blood vs bone marrow. Cases of potentially lethal acute hemolysis have recently been reported after allogeneic PBSCT in the presence of a 'minor' ABO incompatibility. Patients were frequently transfused with recipient-compatible and donor-incompatible RBC and usually did not receive methotrexate in addition to cyclosporin A for graft-versus-host disease (GVHD) prophylaxis. In order to homogenize immuno-hematological (IH) assessment and transfusion practices within our protocol, we made proposals to 25 allo-transplant French centers on the following aspects: pre-inclusion IH assessment, IH exclusion criteria, transfusion rules, post-transplant IH surveillance and treatment of hemolysis. Analysis of responses to our proposals led to the elaboration of guidelines which were approved and implemented by the French Bone Marrow Transplantation Society (SFGM). Pre-inclusion IH testing includes mandatory detection and titration of anti-RBC allo-Ab, as well as titration of anti-A and anti-B Ab. The presence in the donor of an anti-A (group A or AB recipients), anti-B (group B or AB recipients) Ab with a titer >1/32 or the presence of allo-Ab against Rh, Kell, Fya, Fyb, Jka, Jkb, Ss Ag present on recipient RBC is an exclusion criterion for the protocol. ABO and RhD compatibility of RBC blood products with both HSC donor and recipient is mandatory. A similar compatibility is also required for Rh (other than D) and Kell Ag. If not possible, compatibility of RBC blood products with the HSC donor is mandatory. Lastly, guidelines regarding post-transplantation IH follow-up as well as acute hemolysis treatment have been elaborated. The implementation of these guidelines should contribute to enhancing the quality of transfusion practice after PBSCT. Such an approach will be applied to other aspects of transfusion medicine in the setting of HSC transplantation. Bone Marrow Transplantation(2000) 25, 507-512.
Collapse
Affiliation(s)
- V Lapierre
- Unité de Médecine Transfusionnelle et d'Hémovigilance, Institut Gustave Roussy, Villejuif, France
| | | | | |
Collapse
|
25
|
Abstract
We implemented a systematic computer-assisted validation process for transfusion prescriptions to improve transfusion safety. Assessment of this new approach indicates good adoption of validated transfusion guidelines and a reduction of exposure to blood products and overall costs.
Collapse
|
26
|
Cartron J, Chiaroni J, Mannessier L, Le Pennec P, Lapierre V. Session 5 Immuno-hématologie érythrocytaire. Transfus Clin Biol 2000. [DOI: 10.1016/s1246-7820(00)80048-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
27
|
Hervé P, Lapierre V, Morel P, Tiberghien P. [What present strategies are helpful in improving transfusion safety in France?]. Ann Med Interne (Paris) 1999; 150:623-30. [PMID: 10686644] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/15/2023]
Abstract
Transfusion safety rests on measures ensuring that patients are transfused in accordance with the requirements of state-of-the-art scientific knowledge. This strict attitude is part of a quality approach which now applies to all fields of health. Transfusion is historically characterized by its ambivalence: it was the first medical discipline which integrated Quality Assurance concepts, it was also the first which proved unable to respond adequately in the face of uncontrolled risks. Today transfusion must create a system to rapidly: identify any risk, whether emergent or hypothetical; decide which action should be taken; monitor and assess corrective action; study the medico-economic impact of the whole approach. Quality assurance applies to every stage of the transfusion process, from blood donor to labile blood component recipient. This includes blood donor selection and biological control, labile blood component processing, qualification, transport and conditioning, prescription and distribution of blood components and transfused patient follow-up of. Quality controls, "safety locks", must be implemented at every stage to allow early problem detection, thus avoiding potentially dangerous attitudes and guaranteeing transfusion quality all along the process. Medical prescriptions must follow similar rules and meet Good Practice requirements defined by members of the medical and scientific community. A transfusion should not be prescribed unless it is absolutely necessary. In addition to sanitary surveillance, scientific surveillance must also be implemented to help transferring the findings of fundamental research to transfusion activities and continuously improve transfusion safety. INSERM is initiating sociological studies to identify and better understand donors' attitudes leading to risks. More sensitive tests based on nucleic acid amplification should reduce the incidence of residual viral risks. Various viral cell derivative inactivation techniques are being evaluated: the idea is to remove antigens to suppress the risk of post-transfusion alloimmunization. Numerous R&D; programs address substitution products. Transfusion safety requires all actors in the field of health being equally involved. Putting together experiences and know-how will continuously strengthen the quality approach adopted in transfusion.
Collapse
Affiliation(s)
- P Hervé
- Institut Gustave-Roussy, Villejuif
| | | | | | | |
Collapse
|
28
|
Lapierre V, Tramalloni D, Oubouzar N. [Education of nursing personnel on transfusion safety]. Rev Infirm 1999:38-40. [PMID: 10776323] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/16/2023]
Affiliation(s)
- V Lapierre
- Unité de médecine transfusionnelle et d'hémovigilance, institut Gustave-Roussy, Villejuif
| | | | | |
Collapse
|
29
|
Lapierre V, Tramalloni D, Oubouzar N. [Education of nursing personnel on transfusion safety]. Rev Infirm 1999:40-2. [PMID: 10797806] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 04/14/2023]
Affiliation(s)
- V Lapierre
- Unité de médecine transfusionnelle et d'hémovigilance, institut Gustave-Roussy, Villejuif
| | | | | |
Collapse
|
30
|
Lapierre V, Hervé P. [Transfusion medicine in adults. Perspectives]. Presse Med 1999; 28:1336-40. [PMID: 10442069] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/13/2023] Open
Abstract
ENHANCED SURVEILLANCE: Safety in transfusion medicine involves all the different procedures designed to guarantee safe transfusion in accordance with standards established on the current scientific knowledge. It is thus crucial to continuously monitor scientific advances in order to transfer progress in fundamental research as rapidly as possible to transfusion applications and thus maintain the highest level of safety. RISK REDUCTION: The risk of residual viral contamination might be additionally reduced by the introduction of genomic screening. Several virus inactivation processes are currently under evaluation for products derived from blood cells. The risk of post-transfusion alloimmunization might be reduced by eliminating or masking antigens (immunogens). SUBSTITUTION PRODUCTS: There are several ongoing research and development programs concerning substitution products. Products under study include perfluocarbon emulsions, hemoglobin solutions, membrane fragments, and platelet substitutes.
Collapse
Affiliation(s)
- V Lapierre
- Unité de Médecine Transfusionnelle et d'Hémovigilance, Institut Gustave Roussy, Villejuif.
| | | |
Collapse
|
31
|
Lapierre V, Hervé P. [Indications and utilization of labile blood products]. Presse Med 1999; 28:1321-6. [PMID: 10442067] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/13/2023] Open
Abstract
FUNDAMENTAL PRINCIPLES: Rigorous prescription of labile blood products is a fundamental step in assuring safe transfusion. The clinician must avoid all unnecessary transfusions and choose the most adapted blood product to meet the patient's clinical requirements. TRANSFUSION THERAPY: The patient's immunological situation, past history, prognosis, and potential need for future transfusions must be taken into account in a global approach aimed at determining which transfusion product is most adapted for each individual patient. PACKED RED CELLS: Packed red cells should be prescribed after evaluating the risk of tissue hypoxia in light of the patient's clinical situation. Restrictions on transfusion should be particularly drastic if the anemic state could respond to specific treatment (vitamin B12, iron, folic acid, erythropoietin). PLATELETS: There has been considerable development in platelet transfusion over the last few years, particularly in onco-hematology. Nevertheless, very few clinical studies are available for determining which cases require curative transfusion (solely in case of blood loss) and which situations require preventive transfusion (standard versus apheresis products). The platelet threshold indicating transfusion remains a subject of wide debate. FROZEN FRESH PLASMA: In France, regulatory indications for frozen fresh plasma were established by a ministerial decree and concern situations where a plasma fraction substitution product (medically derived blood product) cannot be prescribed. WHITE BLOOD CELL: The transfusion of this type of product should be reserved for clinical situations determined on a consensus basis between clinicians and hemobiologists.
Collapse
Affiliation(s)
- V Lapierre
- Unité de Médecine Transfusionnelle et d'Hémovigilance, Institut Gustave Roussy, Villejuif.
| | | |
Collapse
|
32
|
Lapierre V, Hervé P. [Mode of preparation of labile blood products--available products]. Presse Med 1999; 28:1314-20. [PMID: 10442066] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/13/2023] Open
Abstract
LABILE BLOOD PRODUCTS: Labile blood products are therapeutic products produced from blood which do not have the characteristics of drugs. This category of products include packed red cells, platelets as well as white cell concentrates and frozen fresh plasma. PACKED RED CELLS AND PLATELET CONCENTRATES: These products used to be prepared from total blood. Specific components can be selected using a cell separator (apheresis). This process has made available platelet apheresis products, white cell concentrates and fresh plasma for therapeutic indications. The major impact of apheresis on blood donation has been to reduce the number of donors required for platelet transfusion. PLASMA: In France, plasma is produced from total blood by fractionation in order to assure the production of blood-derived drugs (albumin, coagulation factors, immunoglobulins, biological glue...). Viral inactivation concerns only detergent solvant viro-inactivated plasma. No therapeutic process has been fully validated for other labile blood products. TRANSFORMATION AND CHARACTERISTICS: Labile blood products may undergo several types of transformation: deplasmatization, plasma volume reduction, cyropreservation, irradiation. Since April 1, 1998, all labile cellular blood products produced in France must be leukocyte-depleted. Additional donor-related characterization (phenotype, CMV negative) may also be determined.
Collapse
Affiliation(s)
- V Lapierre
- Unité de Médecine Transfusionnelle et d'Hémovigilance, Institut Gustave Roussy, Villejuif.
| | | |
Collapse
|
33
|
Lapierre V, Hervé P. [Monitoring and secondary effects of transfusion of labile blood products]. Presse Med 1999; 28:1327-35. [PMID: 10442068] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/13/2023] Open
Abstract
VIRUS RISKS: Since 1991, the medical community has focused what can be termed transfusion phobia on transmissible viral diseases. Such diseases do not however reflect the overall risk of transfusion. The residual virus risk is the risk of not detecting a viral disease in the donor population which is transmissible by blood or blood products. This risk depends on the prevalence of the disease in the donor population, the duration of serological silence period and the sensitivity of the screening tests. Hepatitis B virus is the number one transfusionally transmissible virus (1/30,000 to 1/250,000 blood transfusion units), but the main risk of post-transfusion viral disease is caused by the hepatitic C virus. The residual risk of HIV contamination is in the range of 1/200,000 to 1/2,000,000 transfusion units. There is a possible risk of transmitting non-conventional agents (Creutzfeldt-Jakob) but no estimation can be established to date. OTHER RISKS: Potentially severe post-transfusion complications are not limited to transmissible viral diseases. All transfusions carry the risk of bacterial contamination, endotoxinic shock, circulary overload, and anti-leukocyte alloimmunization. Currently, the most frequent and most severe transfusion risks concern acute intravascular hemolysis subsequent to an ABO error or incompatibility with another antigen system and presence of alloantibodies.
Collapse
Affiliation(s)
- V Lapierre
- Unité de Médecine Transfusionnelle et d'Hémovigilance, Institut Gustave Roussy, Villejuif.
| | | |
Collapse
|
34
|
Affiliation(s)
- V Lapierre
- Unité de médecine transfusionnelle et d'hémovigilance, institut Gustave-Roussy, Villejuif, France
| | | | | |
Collapse
|
35
|
Abstract
Allogeneic peripheral blood hematopoietic stem cell transplantation is being evaluated in a randomized French study comparing the use of peripheral blood stem cells vs. bone marrow graft stem cells. In order to standardize immunohematological (IH) assessment and transfusion practices within our protocol, we made suggestions to 25 allo-transplantation French centers on the following elements: pre-inclusion IH assessment, IH exclusion criteria, transfusion rules, post-transplantation IH surveillance and treatment of hemolysis. The analysis of their responses to our suggestions led us to elaborate recommendations which were approved and implemented by the French Bone Marrow Transplantation Society (SFGM). These recommendations concern the transfusion practice in the general framework of allogeneic hematopoietic stem cell transplantation and can therefore be considered as referential.
Collapse
Affiliation(s)
- V Lapierre
- Institut Gustave Roussy, unité de médecine transfusionnelle et d'hémovigilance, Villejuif, France
| | | | | |
Collapse
|
36
|
Hartmann O, Valteau-Couanet D, Vassal G, Lapierre V, Brugières L, Delgado R, Couanet D, Lumbroso J, Benhamou E. Prognostic factors in metastatic neuroblastoma in patients over 1 year of age treated with high-dose chemotherapy and stem cell transplantation: a multivariate analysis in 218 patients treated in a single institution. Bone Marrow Transplant 1999; 23:789-95. [PMID: 10231141 DOI: 10.1038/sj.bmt.1701737] [Citation(s) in RCA: 90] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
The purpose of this paper is to study prognostic factors in neuroblastoma patients treated with high-dose chemotherapy and hematopoietic stem cell transplantation. Two hundred and eighteen children over 1 year of age and treated for stage 4 neuroblastoma were enrolled in this study. The median age at diagnosis was 39 months, the sex ratio 1.5 and 84% of patients had an abdominal primary tumor. Skeletal disease was detected in 79% of cases and bone marrow involvement in 93%. N-myc oncogene amplification was present in 27% of the patients studied. The probability of event-free survival at 5 years post-diagnosis was 29% in this series. Three major favorable prognostic factors were significant and independent in the multivariate analysis: age under 2 years at diagnosis (P<0.01), absence of bone marrow metastases at diagnosis (P<0.04) and the high-dose conditioning regimen containing busulfanmelphalan combination (P = 0.001). The quality of response to conventional primary chemotherapy was close to significance (P = 0.053). We conclude that factors related to the patient (age) and extent of disease are predictive of outcome in patients with neuroblastoma treated with conventional chemotherapy followed by surgical excision of the primary and consolidation with high-dose chemotherapy. They should be taken into account in future prospective studies. Moreover, the type of conditioning regimen appears to be the most important prognostic factor. This should encourage new investigations into innovative drug combinations.
Collapse
Affiliation(s)
- O Hartmann
- Pediatrics Department, Institut Gustave Roussy, Villejuif, France
| | | | | | | | | | | | | | | | | |
Collapse
|
37
|
Lapierre V, Aupérin A, Benhamou E, Tursz T. A specific approval procedure for prescribing albumin: impact on consumption in a cancer treatment institution. Ann Oncol 1999; 10:244-5. [PMID: 10093699 DOI: 10.1023/a:1008311616757] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
38
|
Lucidarme N, Valteau-Couanet D, Oberlin O, Couanet D, Kalifa C, Beaujean F, Lapierre V, Hartmann O. Phase II study of high-dose thiotepa and hematopoietic stem cell transplantation in children with solid tumors. Bone Marrow Transplant 1998; 22:535-40. [PMID: 9758339 DOI: 10.1038/sj.bmt.1701395] [Citation(s) in RCA: 44] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
From 1987 to 1995, 22 children with refractory solid tumors entered a phase II study of high-dose thiotepa (HDT) (900 mg/m2) followed by stem cell transplantation (SCT) in the Pediatrics Department of the Institut Gustave Roussy. Tumor types were rhabdomyosarcoma (eight), osteosarcoma (seven), neuroblastoma (three), Ewing's sarcoma (three) and Burkitt's lymphoma (one). Before HDT, all had been extensively treated with conventional chemotherapy, surgical resection of the primary tumor (13/22) and of metastases (6/22), and radiotherapy of the primary tumor in three patients. All had measurable disease, at the site of the primary tumor (3 patients), of the metastases (9 patients) or both (10 patients). Toxicity from the HDT was severe but acceptable. No toxicity-related death occurred. The median duration of neutropenia and thrombocytopenia was 18 days (5-37) and 30 days (7-377), respectively. Septicemia was documented in four patients. Severe diarrhea was observed in seven patients. Mild hepatic toxicity occurred 18 times. No CR and 11/22 PR were documented: osteosarcoma 4/7, rhabdomyosarcoma 4/8, Ewing's sarcoma 2/3; 1/1 Burkitt's lymphoma progressed. We conclude that at a dose of 900 mg/m2 followed by SCT support in these heavily pretreated children, the main toxicity induced by thiotepa was digestive. The response rate observed, especially in sarcoma, is particularly encouraging. Thiotepa should be further evaluated in HDC regimens either in combination with other alkylating agents or in rapidly cycled courses of HDC with SCT.
Collapse
Affiliation(s)
- N Lucidarme
- Pediatrics Department, Institut Gustave Roussy, Villejuif, France
| | | | | | | | | | | | | | | |
Collapse
|
39
|
Affiliation(s)
- V Lapierre
- Unité de Médecine Transfusionnelle et d'Hémovigilance, Institut Gustave Roussy, Villejuif, France.
| | | | | |
Collapse
|
40
|
Lapierre V, Ferrand C, Tramalloni D, Oubouzar N, Paris C, Chabod J, Debane B, Benhamou E, Tiberghien P. O20-1 Étude de l'immunomodulation post-transfusion chez des patients bénéficiant d'une chirurgie carcinologique (étude transfuge). Transfus Clin Biol 1998. [DOI: 10.1016/s1246-7820(98)80314-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
41
|
Lapierre V, Tiberghien P, Kuentz M, pour la Société française de gref. O2bis-7 Homogénéisation des pratiques transfusionnelles après greffe de cellules souches hématopoïétiques allogéniques provenant du sang périphérique. Transfus Clin Biol 1998. [DOI: 10.1016/s1246-7820(98)80026-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
42
|
Beaussier P, Vasselon S, Brault P, Benhamou E, Valteau-Couanet D, Lapierre V, Hartmann O. Peripheral stem cell collection (PSCC) in children. It seems to be easy: Review of the problems encountered. Eur J Cancer 1997. [DOI: 10.1016/s0959-8049(97)86403-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
43
|
Elias D, Lapierre V. [Blood transfusions in cancer patients]. Presse Med 1996; 25:255-8. [PMID: 8729329] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/01/2023] Open
Abstract
In this review, we develop four topics on the relationship between blood transfusion and cancer. First, the rationale for not allowing blood donations from patients with infiltrating tumors is presented. Second, the different possibilities for autotransfusions in cancer patients are discussed. Predeposited autotransfusions are rarely possible in these patients, in addition to the high cost. The usefulness of another method, intraoperative autologous transfusion with blood saved from the surgical field, is not well established. Our third topic concerns the effect of transfusion on cancer induction. In some cases, the risk of cancer is higher after allogenic transfusion resulting from a mechanism involving alterations of the immune function. Finally, the relationship between transfusion and cancer recurrence is controversial. In spite of numerous studies attempting to elucidate this relationship, no final conclusion can be drawn at the present time. What is sure, is that patients requiring blood transfusion have a higher risk of recurrence than patients who do not need transfusion.
Collapse
Affiliation(s)
- D Elias
- Service de Chirurgie digestive carcinologique, Institut Gustave Roussy, Villejuif
| | | |
Collapse
|
44
|
Valteau-Couanet D, Benhamou E, Oberlin O, Couanet D, Lapierre V, Beaujean F, Hartmann O. 1201 Consolidation with Busulfan and Melphalan followed by hematopoietic stem-cell transplantation (SCT) in children with poor prognosis Ewing's sarcoma. Eur J Cancer 1995. [DOI: 10.1016/0959-8049(95)96447-l] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
45
|
|
46
|
Charpentier F, Bierling P, Lapierre V, Duedari N. [Passive transmission of granulo-agglutinating anti-HLA antibodies without pulmonary involvement]. Rev Fr Transfus Hemobiol 1993; 36:317-9. [PMID: 8357443 DOI: 10.1016/s1140-4639(05)80236-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
|
47
|
Pico JL, Marie JP, Chiche D, Guiguet M, Andremont A, Lapierre V, Richet H, Tancrede C, Lagrange P, Hayat M. Should vancomycin be used empirically in febrile patients with prolonged and profound neutropenia? Results of a randomized trial. Eur J Med 1993; 2:275-80. [PMID: 8252157] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
OBJECTIVES We conducted a randomized trial with ceftazidine alone or associated with amikacin or vancomycin to investigate the efficacy of the daily 3 g dosage of ceftazidime and the efficacy of monotherapy with ceftazidime and to determine if vancomycin should be added empirically. METHODS Patient inclusion criteria were: age over 10 years, therapeutically-induced neutropenia and fever for at least three hours above 38.5 degrees C in absence of a clear non-infectious aetiology. Patients were randomized into three groups: group C, ceftazidime alone 3 g/day; group CA, ceftazidime 3 g/day plus amikacin 15 mg/kg/day; or group C, ceftazidime 3 g/day plus vancomycin 1.5 g/day. RESULTS Results from one hundred and two episodes of fever were analyzed. The underlying diseases were haematological malignancies (89 patients) and solid tumours (13 patients). The median duration of neutropenia (< 0.5 x 10(9) PMN/L) was 18 days and the minimum duration of 7 days. The main criterion for the analysis of efficacy was the onset of a major infectious event, i.e. death related to documented or suspected infection and any infectious event considered life-threatening or hindering future treatment of the underlying disease. Eight (22%) patients in group C developed major infectious events compared with four (13%) in group CA and none in group CV (p < 0.01). Major infectious events were mainly due to Gram-positive organisms, particularly Streptococcus species. CONCLUSION We conclude that: 1) ceftazidime alone and in association with amikacin is effective in preventing Gram-negative major infectious events; and 2) vancomycin should not be added only when a Gram-positive infection is documented, but used empirically.
Collapse
Affiliation(s)
- J L Pico
- Service d'Hématologie, Institut Gustave Roussy, Villejuif, France
| | | | | | | | | | | | | | | | | | | |
Collapse
|
48
|
Marie J, Pico J, Lapierre V, Maulard C, Pappo M, Chiche D, Andremont A, Lagrange P, Hayat M, Zittoun R. Traitement empirique des épisodes fébriles survenant chez les patients cancéreux présentant une neutropénie prolongée : essai comparatif ceftazidime seule, ceftazidime + amikacine et ceftazidime + vancomycine. Med Mal Infect 1991. [DOI: 10.1016/s0399-077x(05)80140-4] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
49
|
Abstract
1. The effects of verapamil (120 mg orally) and a placebo on arterial pressure, heart rate, PR interval, arterial flows and diameters of the brachial and carotid arteries (pulsed Doppler technique), forearm vascular resistance, and venous diameter and compliance (cutaneous microstrain gauge and plethysmography) have been compared over a 10-hr period in six healthy volunteers during a double-blind and cross-over study. 2. Verapamil reduced diastolic blood pressure by approximately 10 mm Hg, did not affect heart rate and increased PR interval by approximately 15%. 3. Verapamil significantly increased brachial and carotid arterial blood flows by 56% (P less than 0.01) and 16% (P less than 0.05), respectively, but the diameters of these vessels were not significantly modified (+7 and +4%, respectively, NS). Forearm vascular resistance decreased by 40% (P less than 0.01), indicating that verapamil preferentially dilates small arteries. All these effects peaked at 2 h after drug intake and lasted for 6 h. 4. Verapamil increased hand dorsal vein diameter and flow by 95% (P less than 0.05) and 80% (P less than 0.05), respectively, from 2 to 4 h after drug intake but venous compliance, assessed by the venous diameter/venous flow ratio, was not significantly modified (from 0.71 to 0.69, NS), thus indicating that veins are not directly affected by this drug.
Collapse
Affiliation(s)
- C Thuillez
- Service de Pharmacologie Clinique, Hôpital de Bicêtre, Le Kremlin-Bicêtre, France
| | | | | | | | | |
Collapse
|